Caladrius Biosciences to Host Third Quarter 2021 Financial Results Conference Call on Thursday, November 4th at 4:30 p.m. Eastern Time
October 28 2021 - 7:00AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company
dedicated to the development of cellular therapies designed to
reverse disease, today announced that the Company will report its
financial results for the three months ended September 30, 2021, on
Thursday, November 4, 2021, at 4:30 p.m. (ET). To join the live
conference call, please refer to the dial-in information provided
below.
Dial-in information: Conference
ID: 8378269U.S. Toll-Free:
866-595-8403International: 706-758-9979
A live webcast of the call will be available on the
Caladrius website under the Investors & News section. A replay
of the webcast will also be available for 90 days following the
conclusion of the call.
For those unable to participate on the live
conference call, an audio replay will also be available that day
starting at 7:30 p.m. (ET) until November 11, 2021, by dialing
855-859-2056 (U.S. Toll-Free) or 404-537-3406 (International) and
by entering the conference ID: 8378269.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include:
XOWNA® (CLBS16), the subject of both a recently completed positive
Phase 2a study and a newly initiated Phase 2b study
(www.freedom-trial.com) in the U.S. for the treatment of coronary
microvascular dysfunction (“CMD”); CLBS12 (HONEDRA® in Japan),
recipient of orphan designation for Buerger’s Disease in the
U.S. and, in Japan, recipient of a SAKIGAKE designation and
eligible for early conditional approval for the treatment of
critical limb ischemia (“CLI”) and Buerger’s Disease based on the
results of an ongoing clinical trial; and CLBS201, designed to
assess the safety and efficacy of CD34+ cell therapy as a treatment
for diabetic kidney disease (“DKD). For more information on
the Company, please visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John
MendittoVice President, Investor Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@caladrius.com
Media: Real ChemistryRachel GirardReal
ChemistryPhone: 401-477-4030Email: rgirard@realchemistry.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2024 to May 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From May 2023 to May 2024